KCNQ1 and non-small cell lung carcinoma: However, KCNQ1-inhibitor gefitinib, which is the first-generation targeted therapy for non-small cell lung cancer, was implicated in the induction of heart QT prolongation in a guinea pig model, thereby raising a concern of arrhythmia when gefitinib is used for NSCLC treatment (80).